Robyn H. Guymer

List of Publications by Citations

329 papers	12,614 citations	59 h-index	99 g-index
356 ext. papers	15,356 ext. citations	5.1 avg, IF	6.31 L-index

#	Paper	IF	Citations
329	A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature Genetics*, **2016**, 48, 134-43	36.3	769
328	Seven new loci associated with age-related macular degeneration. *Nature Genetics*, **2013**, 45, 433-9, 439e1-2	36.3	577
327	A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. *Nature Genetics*, **1999**, 22, 199-202	36.3	384
326	Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. *Ophthalmology*, **2011**, 118, 663-71	7.3	304
325	Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. *Ophthalmology*, **2011**, 118, 831-9	7.3	295
324	Automatic segmentation of nine retinal layer boundaries in OCT images of non-exudative AMD patients using deep learning and graph search. *Biomedical Optics Express*, **2017**, 8, 2732-2744	3.5	285
323	Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3. *Ophthalmology*, **2018**, 125, 537-548	7.3	253
322	Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. *Human Molecular Genetics*, **2011**, 20, 3699-709	5.6	205
321	First-in-human trial of a novel suprachoroidal retinal prosthesis. *PLoS ONE*, **2014**, 9, e115239	3.7	201
320	Perifoveal m□ller cell depletion in a case of macular telangiectasia type 2. *Ophthalmology*, **2010**, 117, 2407-16	7.3	184
319	Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. *JAMA Ophthalmology*, **2008**, 126, 826-33		184
318	Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. *Ophthalmology*, **2020**, 127, 616-636	7.3	154
317	Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. *Ophthalmology*, **2014**, 121, 2415-22	7.3	153
316	Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. *Ophthalmology*, **2015**, 122, 1837-45	7.3	152
315	Heritability of refractive error and ocular biometrics: the Genes in Myopia (GEM) twin study. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 4756-61		152
314	Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis. *BMJ, The*, **2007**, 335, 755	5.9	146
313	The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 1311-5		139

312	Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. *Cell Reports*, **2012**, 2, 1151-8	10.6	130
311	Identification of a rare coding variant in complement 3 associated with age-related macular degeneration. *Nature Genetics*, **2013**, 45, 1375-9	36.3	130
310	Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization. *Ophthalmology*, **2014**, 121, 1252-6	7.3	116
309	Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. *Ophthalmology*, **2015**, 122, 1212-9	7.3	116
308	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. *Ophthalmology*, **2019**, 126, 723-734	7.3	116
307	Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. *Ophthalmology*, **2017**, 124, 464-478	7.3	110
306	Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. *Survey of Ophthalmology*, **2014**, 59, 1-18	6.1	100
305	Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. *Human Mutation*, **2011**, 32, 1407-16	4.7	99
304	Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. *Retina*, **2014**, 34, 1531-8	3.6	96
303	Fat consumption and its association with age-related macular degeneration. *JAMA Ophthalmology*, **2009**, 127, 674-80		95
302	Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. *Ophthalmology*, **2008**, 115, 1911-5	7.3	95
301	Visual function tests as potential biomarkers in age-related macular degeneration **2011**, 52, 9457-69		93
300	Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. *New England Journal of Medicine*, **2019**, 381, 1422-1433	59.2	91
299	Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. *Ophthalmology*, **2019**, 126, 829-838	7.3	89
298	Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. *American Journal of Ophthalmology*, **2012**, 153, 678-86, 686.e1-2	4.9	88
297	Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). *Human Mutation*, **2006**, 27, 337-42	4.7	88
296	Intrasession test-retest variability of microperimetry in age-related macular degeneration **2013**, 54, 7378-85		87
295	Measuring rod and cone dynamics in age-related maculopathy. *Investigative Ophthalmology and Visual Science*, **2008**, 49, 55-65		86

294	Variation of codons 1961 and 2177 of the Stargardt disease gene is not associated with age-related macular degeneration. *JAMA Ophthalmology*, **2001**, 119, 745-51		84
293	Loss of cone function in age-related maculopathy. *Investigative Ophthalmology and Visual Science*, **2003**, 44, 2277-83		79
292	Correlation of Histologic Features with In Vivo Imaging of Reticular Pseudodrusen. *Ophthalmology*, **2016**, 123, 1320-31	7.3	77
291	Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. *Human Molecular Genetics*, **2008**, 17, 1299-305	5.6	75
290	Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. *Retina*, **2014**, 34, 188-95	3.6	74
289	Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage. *FASEB Journal*, **2015**, 29, 696-710	0.9	73
288	The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. *Ophthalmology*, **2013**, 120, 130-9	7.3	73
287	Alcohol consumption and the risk of age-related macular degeneration: a systematic review and meta-analysis. *American Journal of Ophthalmology*, **2008**, 145, 707-715	4.9	73
286	Abdominal obesity and age-related macular degeneration. *American Journal of Epidemiology*, **2011**, 173, 1246-55	3.8	72
285	Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial. *Ophthalmology*, **2019**, 126, 540-549	7.3	72
284	The prevalence and risk factors of epiretinal membranes: the Melbourne Collaborative Cohort Study. *Retina*, **2013**, 33, 1026-34	3.6	71
283	Age-related macular degeneration. *Nature Reviews Disease Primers*, **2021**, 7, 31	51.1	71
282	Reticular Pseudodrusen and Their Association with Age-Related Macular Degeneration: The Melbourne Collaborative Cohort Study. *Ophthalmology*, **2016**, 123, 599-608	7.3	70
281	Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 4194-8		68
280	Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. *American Journal of Epidemiology*, **2011**, 173, 1357-64	3.8	67
279	Incomplete Retinal Pigment Epithelial and Outer Retinal Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 4. *Ophthalmology*, **2020**, 127, 394-409	7.3	67
278	Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. *Ophthalmology*, **2013**, 120, 115-21	7.3	63
277	Animal models of retinal disease. *Progress in Molecular Biology and Translational Science*, **2011**, 100, 211-86		63

276	Low-luminance visual acuity and microperimetry in age-related macular degeneration. *Ophthalmology*, **2014**, 121, 1612-9	7.3	61
275	Flicker perimetry losses in age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 3355-60		61
274	Exposure to Chlamydia pneumoniae infection and progression of age-related macular degeneration. *American Journal of Epidemiology*, **2005**, 161, 1013-9	3.8	60
273	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. *JAMA Ophthalmology*, **2019**, 137, 372-379	3.9	59
272	Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. *Ophthalmology*, **2013**, 120, 1641-8	7.3	59
271	Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. *JAMA Ophthalmology*, **2015**, 133, 442-8	3.9	59
270	Choroidal thickness profiles in retinitis pigmentosa. *Clinical and Experimental Ophthalmology*, **2013**, 41, 396-403	2.4	59
269	Modifiable risk factors for age-related macular degeneration. *Medical Journal of Australia*, **2006**, 184, 455-8	4	59
268	TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. *Retina*, **2018**, 38, 20-28	3.6	58
267	Advances in implantable bionic devices for blindness: a review. *ANZ Journal of Surgery*, **2016**, 86, 654-9	1	58
266	Drusen in patient-derived hiPSC-RPE models of macular dystrophies. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E8214-E8223	11.5	57
265	Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. *Medical Journal of Australia*, **2001**, 175, 340	4	57
264	Relationship between retinal microstructures on optical coherence tomography and microperimetry in age-related macular degeneration. *Ophthalmology*, **2014**, 121, 1445-52	7.3	55
263	The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study. *BMC Ophthalmology*, **2016**, 16, 31	2.3	54
262	Dietary patterns and their associations with age-related macular degeneration: the Melbourne collaborative cohort study. *Ophthalmology*, **2014**, 121, 1428-1434.e2	7.3	52
261	C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. *Ophthalmology*, **2010**, 117, 1982-8	7.3	52
260	Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration. *PLoS ONE*, **2013**, 8, e83759	3.7	52
259	A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration. *FASEB Journal*, **2013**, 27, 1479-87	0.9	49

258	20/20--Alcohol and age-related macular degeneration: the Melbourne Collaborative Cohort Study. *American Journal of Epidemiology*, **2012**, 176, 289-98	3.8	49
257	Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. *Clinical and Experimental Ophthalmology*, **2014**, 42, 466-79	2.4	47
256	Relationship between clinical macular changes and retinal function in age-related macular degeneration **2012**, 53, 5213-20		46
255	The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study. *Retina*, **2010**, 30, 473-8	3.6	46
254	Laser treatment in subjects with high-risk clinical features of age-related macular degeneration. Posterior pole appearance and retinal function. *JAMA Ophthalmology*, **1997**, 115, 595-603		46
253	Red meat and chicken consumption and its association with age-related macular degeneration. *American Journal of Epidemiology*, **2009**, 169, 867-76	3.8	45
252	HMG CoA reductase inhibitors (statins): do they have a role in age-related macular degeneration?. *Survey of Ophthalmology*, **2005**, 50, 194-206	6.1	45
251	Ellipsoid zone on optical coherence tomography: a review. *Clinical and Experimental Ophthalmology*, **2016**, 44, 422-30	2.4	45
250	Therapeutic targeting of the complement system in age-related macular degeneration: a review. *Clinical and Experimental Ophthalmology*, **2012**, 40, 18-26	2.4	44
249	Reticular Pseudodrusen in Intermediate Age-Related Macular Degeneration: Prevalence, Detection, Clinical, Environmental, and Genetic Associations **2016**, 57, 1310-6		44
248	Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration. *Human Genomics*, **2011**, 5, 420-40	6.8	43
247	Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD **2011**, 52, 4072-9		43
246	The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis. *American Journal of Ophthalmology*, **2018**, 192, 184-197	4.9	42
245	Low luminance deficit and night vision symptoms in intermediate age-related macular degeneration. *British Journal of Ophthalmology*, **2016**, 100, 395-8	5.5	40
244	Impact of cataract surgery on quality of life in patients with early age-related macular degeneration. *Optometry and Vision Science*, **2007**, 84, 683-8	2.1	40
243	Fundus autofluorescence characteristics of nascent geographic atrophy in age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2015**, 56, 1546-52		39
242	The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. *Ophthalmology*, **2014**, 121, 1246-51	7.3	39
241	New treatments in age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2003**, 31, 376-91	2.4	39

240	Physical Activity and Age-related Macular Degeneration: A Systematic Literature Review and Meta-analysis. *American Journal of Ophthalmology*, **2017**, 180, 29-38	4.9	38
239	Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD) **2009**, 50, 540-3		38
238	Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. *American Journal of Ophthalmology*, **2006**, 141, 276-81	4.9	38
237	Association of the M55L and Q192R paraoxonase gene polymorphisms with age-related macular degeneration. *American Journal of Ophthalmology*, **2004**, 138, 665-6	4.9	38
236	Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. *JAMA Ophthalmology*, **2015**, 133, 647-52	3.9	36
235	Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. *Ophthalmology*, **2014**, 121, 676-81	7.3	36
234	Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. *Canadian Journal of Ophthalmology*, **2007**, 42, 720-6	1.4	36
233	IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL. *Retina*, **2016**, 36, 1331-9	3.6	36
232	Microperimetry of nascent geographic atrophy in age-related macular degeneration. *Investigative Ophthalmology and Visual Science*, **2014**, 56, 115-21		35
231	Impact of reticular pseudodrusen on microperimetry and multifocal electroretinography in intermediate age-related macular degeneration **2015**, 56, 2100-6		35
230	Identification of urinary biomarkers for age-related macular degeneration **2011**, 52, 4639-44		35
229	Longitudinal Associations Between Microstructural Changes and Microperimetry in the Early Stages of Age-Related Macular Degeneration **2016**, 57, 3714-22		35
228	A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. *Molecular Vision*, **2007**, 13, 2148-52	2.3	35
227	Development of a surgical procedure for implantation of a prototype suprachoroidal retinal prosthesis. *Clinical and Experimental Ophthalmology*, **2014**, 42, 665-74	2.4	34
226	Unraveling a complex genetic disease: age-related macular degeneration. *Survey of Ophthalmology*, **2006**, 51, 576-86	6.1	34
225	Assessment of Retinotopic Rod Photoreceptor Function Using a Dark-Adapted Chromatic Perimeter in Intermediate Age-Related Macular Degeneration **2016**, 57, 5436-5442		34
224	Classification of healthy and diseased retina using SD-OCT imaging and Random Forest algorithm. *PLoS ONE*, **2018**, 13, e0198281	3.7	34
223	Cataract surgery in high-risk age-related macular degeneration: a randomized controlled trial. *Clinical and Experimental Ophthalmology*, **2009**, 37, 570-6	2.4	33

222	Relationship between the second reflective band on optical coherence tomography and multifocal electroretinography in age-related macular degeneration **2013**, 54, 2800-6		32
221	Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. *Cost Effectiveness and Resource Allocation*, **2008**, 6, 12	2.4	32
220	Alzheimer's Disease and the Early Signs of Age-Related Macular Degeneration. *Current Alzheimer Research*, **2016**, 13, 1259-1266	3	32
219	Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration. *Ophthalmology*, **2016**, 123, 2393-2400	7.3	31
218	Comparison between multifocal electroretinography and microperimetry in age-related macular degeneration **2014**, 55, 6431-9		31
217	Central retinal function as measured by the multifocal electroretinogram and flicker perimetry in early age-related macular degeneration **2011**, 52, 9267-74		31
216	The Experience of Age-related Macular Degeneration. *Journal of Visual Impairment and Blindness*, **2004**, 98, 629-640	0.7	31
215	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer's disease. *Acta Neuropathologica*, **2016**, 132, 377-89	14.3	30
214	Test-Retest Repeatability of Microperimetry at the Border of Deep Scotomas **2015**, 56, 2606-11		30
213	Cytoarchitecture of choroidal capillary endothelial cells. *Investigative Ophthalmology and Visual Science*, **2004**, 45, 1660-6		30
212	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. *British Journal of Ophthalmology*, **2016**, 100, 1640-1645	5.5	30
211	Developing the impact of Vision Impairment-Very Low Vision (IVI-VLV) questionnaire as part of the LoVADA protocol **2014**, 55, 6150-8		29
210	Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences. *PLoS ONE*, **2013**, 8, e81042	3.7	29
209	Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes **2013**, 54, 5754-60		29
208	Blood storage at 4 degrees C-factors involved in DNA yield and quality. *Translational Research*, **2006** , 147, 290-4		29
207	Urocanic acid as an immunosuppressant in allotransplantation in mice. *Transplantation*, **1993**, 55, 36-43	1.8	29
206	Scheduled versus Pro Re Nata Dosing in the VIEW Trials. *Ophthalmology*, **2015**, 122, 2497-503	7.3	28
205	Development and validation of a deep-learning algorithm for the detection of neovascular age-related macular degeneration from colour fundus photographs. *Clinical and Experimental Ophthalmology*, **2019**, 47, 1009-1018	2.4	27

204	ATP-induced photoreceptor death in a feline model of retinal degeneration. *Investigative Ophthalmology and Visual Science*, **2014**, 55, 8319-29		27
203	Exposure to Chlamydia pneumoniae infection and age-related macular degeneration: the Blue Mountains Eye Study. *Investigative Ophthalmology and Visual Science*, **2007**, 48, 4007-11		26
202	Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. *Expert Review of Clinical Pharmacology*, **2015**, 8, 541-8	3.8	25
201	Apolipoprotein E gene associations in age-related macular degeneration: the Melbourne Collaborative Cohort Study. *American Journal of Epidemiology*, **2012**, 175, 511-8	3.8	25
200	Characteristics of progression of early age-related macular degeneration: the cardiovascular health and age-related maculopathy study. *Eye*, **2007**, 21, 169-76	4.4	25
199	Imaging Features Associated with Progression to Geographic Atrophy in Age-Related Macular Degeneration: Classification of Atrophy Meeting Report 5. *Ophthalmology Retina*, **2021**, 5, 855-867	3.8	25
198	Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H () gene family. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4433-E4442	11.5	24
197	Restorative retinal laser therapy: Present state and future directions. *Survey of Ophthalmology*, **2018**, 63, 307-328	6.1	24
196	Iris colour, ethnic origin and progression of age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2003**, 31, 465-9	2.4	24
195	Reticular pseudodrusen: current understanding. *Australasian journal of optometry, The*, **2019**, 102, 455-462	1.7	24
194	Subthreshold Nanosecond Laser Intervention in Intermediate Age-Related Macular Degeneration: Study Design and Baseline Characteristics of the Laser in Early Stages of Age-Related Macular Degeneration Study (Report Number 1). *Ophthalmology Retina*, **2017**, 1, 227-239	3.8	23
193	New era for personalized medicine: the diagnosis and management of age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2009**, 37, 814-21	2.4	23
192	Analysis of the EFEMP1 gene in individuals and families with early onset drusen. *Eye*, **2005**, 19, 11-5	4.4	23
191	Age-Related Macular Degeneration and Mortality: A Systematic Review and Meta-Analysis. *Ophthalmic Epidemiology*, **2017**, 24, 141-152	1.9	22
190	Loss of Function of P2X7 Receptor Scavenger Activity in Aging Mice: A Novel Model for Investigating the Early Pathogenesis of Age-Related Macular Degeneration. *American Journal of Pathology*, **2017**, 187, 1670-1685	5.8	22
189	Role of flicker perimetry in predicting onset of late-stage age-related macular degeneration. *JAMA Ophthalmology*, **2012**, 130, 690-9		22
188	Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2002**, 30, 419-23	2.4	22
187	Static and flicker perimetry in age-related macular degeneration **2013**, 54, 3560-8		21

186	Characterization of the peripheral retinopathy in X-linked and autosomal recessive Alport syndrome. *Nephrology Dialysis Transplantation*, **2007**, 22, 104-8	4.3	21
185	Methodology of the Cardiovascular Health and Age-Related Maculopathy (CHARM) Study. *Ophthalmic Epidemiology*, **2004**, 11, 161-79	1.9	21
184	Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. *Ophthalmology*, **2015**, 122, 589-594.e1	7.3	20
183	Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The age-related maculopathy statin study (ARMSS). *Clinical Interventions in Aging*, **2008**, 3, 581-93	4	20
182	Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degeneration: Systematic Literature Review and Expert Opinion. *Ophthalmology*, **2020**, 127, 648-659	7.3	20
181	Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in Age-Related Macular Degeneration. *Ophthalmology Retina*, **2020**, 4, 568-575	3.8	20
180	Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. *JAMA Ophthalmology*, **2018**, 136, 875-884	3.9	20
179	Multiallelic copy number variation in the complement component 4A (C4A) gene is associated with late-stage age-related macular degeneration (AMD). *Journal of Neuroinflammation*, **2016**, 13, 81	10.1	19
178	Developing an instrumental activities of daily living tool as part of the low vision assessment of daily activities protocol. *Investigative Ophthalmology and Visual Science*, **2014**, 55, 8458-66		19
177	Chlamydia pneumoniae and age-related macular degeneration: a role in pathogenesis or merely a chance association?. *Clinical and Experimental Ophthalmology*, **2007**, 35, 89-93	2.4	19
176	Facts on fats. *Clinical and Experimental Ophthalmology*, **2006**, 34, 464-71	2.4	19
175	Treatment of age-related macular degeneration. *Australasian journal of optometry, The*, **2005**, 88, 322-34	2.7	19
174	Longitudinal Changes in Retinotopic Rod Function in Intermediate Age-Related Macular Degeneration **2018**, 59, AMD19-AMD24		19
173	Quantitative Analysis of the Ellipsoid Zone Intensity in Phenotypic Variations of Intermediate Age-Related Macular Degeneration **2017**, 58, 2079-2086		18
172	Automatic Identification of Pathology-Distorted Retinal Layer Boundaries Using SD-OCT Imaging. *IEEE Transactions on Biomedical Engineering*, **2017**, 64, 1638-1649	5	18
171	Determining the Contribution of Retinotopic Discrimination to Localization Performance With a Suprachoroidal Retinal Prosthesis **2017**, 58, 3231-3239		18
170	Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened Bruch's membrane **2014**, 55, 460-8		18
169	Can genetic associations change with age? CFH and age-related macular degeneration. *Human Molecular Genetics*, **2012**, 21, 5229-36	5.6	18

168	Heritability of macular thickness determined by optical coherence tomography. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 336-40		18
167	GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration. *Scientific Reports*, **2016**, 6, 37924	4.9	18
166	Past physical activity and age-related macular degeneration: the Melbourne Collaborative Cohort Study. *British Journal of Ophthalmology*, **2016**, 100, 1353-8	5.5	18
165	Measurement of Retinal Sensitivity on Tablet Devices in Age-Related Macular Degeneration. *Translational Vision Science and Technology*, **2015**, 4, 13	3.3	17
164	Comprehensive analysis of Copy Number Variation of genes at chromosome 1 and 10 loci associated with late age related macular degeneration. *PLoS ONE*, **2012**, 7, e35255	3.7	17
163	The longitudinal impact of macular telangiectasia (MacTel) type 2 on vision-related quality of life **2011**, 52, 2520-4		17
162	Influence of laser photocoagulation on choroidal capillary cytoarchitecture. *British Journal of Ophthalmology*, **2001**, 85, 40-6	5.5	17
161	Prophylactic laser treatment to fellow eyes of unilateral retinal pigment epithelial tears. *American Journal of Ophthalmology*, **1998**, 126, 77-81	4.9	17
160	Fluorescein angiographic abnormalities after prophylactic macular photocoagulation for high-risk age-related maculopathy. *American Journal of Ophthalmology*, **1999**, 127, 681-7	4.9	17
159	Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials. *Progress in Retinal and Eye Research*, **2021**, 82, 100907	20.5	17
158	Role of lysophosphatidic acid in the retinal pigment epithelium and photoreceptors. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2018**, 1863, 750-761	5	16
157	Second reflective band intensity in age-related macular degeneration. *Ophthalmology*, **2013**, 120, 1307-8, e1	7.5	16
156	A comparison of corneal, pancreas, and skin grafts in mice. A study of the determinants of tissue immunogenicity. *Transplantation*, **1994**, 57, 1251-62	1.8	16
155	Stimulation of a Suprachoroidal Retinal Prosthesis Drives Cortical Responses in a Feline Model of Retinal Degeneration **2016**, 57, 5216-5229		16
154	Developing a Very Low Vision Orientation and Mobility Test Battery (O&M-VLV). *Optometry and Vision Science*, **2016**, 93, 1127-36	2.1	15
153	Secondary and Exploratory Outcomes of the Subthreshold Nanosecond Laser Intervention Randomized Trial in Age-Related Macular Degeneration: A LEAD Study Report. *Ophthalmology Retina*, **2019**, 3, 1026-1034	3.8	15
152	An intergenic region between the tagSNP rs3793917 and rs11200638 in the HTRA1 gene indicates association with age-related macular degeneration **2010**, 51, 4932-6		15
151	Non-mydriatic Digital Macular Photography: How Good is the Second Eye Photograph?. *Ophthalmic Epidemiology*, **2009**, 16, 254-261	1.9	15

150	Ranibizumab treatment for neovascular age-related macular degeneration: from randomized trials to clinical practice. *Eye*, **2009**, 23, 1633-40	4.4	15
149	Structural OCT Signs Suggestive of Subclinical Nonexudative Macular Neovascularization in Eyes with Large Drusen. *Ophthalmology*, **2020**, 127, 637-647	7.3	15
148	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. *Ophthalmology*, **2019**, 126, 64-74	7.3	15
147	Microperimetry for geographic atrophy secondary to age-related macular degeneration. *Survey of Ophthalmology*, **2019**, 64, 353-364	6.1	14
146	Predictors of AMD treatment response. *Ophthalmology*, **2012**, 119, 2413-2414.e5	7.3	14
145	Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital. *Clinical and Experimental Ophthalmology*, **2003**, 31, 476-81	2.4	14
144	Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials. *Ophthalmology Retina*, **2020**, 4, 673-688	3.8	14
143	Progress in the clinical development and utilization of vision prostheses: an update. *Eye and Brain*, **2016**, 8, 15-25	5.7	14
142	Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). *Ophthalmology*, **2020**, 127, 198-210	7.3	14
141	Refractive errors in twin studies. *Twin Research and Human Genetics*, **2006**, 9, 566-72	2.2	14
140	Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. *British Journal of Ophthalmology*, **2015**, 99, 359-64	5.5	13
139	Subretinal Drusenoid Deposits and the Loss of Rod Function in Intermediate Age-Related Macular Degeneration **2018**, 59, 4154-4161		13
138	Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes. *Clinical and Experimental Ophthalmology*, **2012**, 40, 67-72	2.4	13
137	Best's macular dystrophy in Australia: phenotypic profile and identification of novel BEST1 mutations. *Eye*, **2011**, 25, 208-17	4.4	13
136	Disclosing disease mechanisms with a spatio-temporal summation paradigm. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2006**, 244, 425-32	3.8	13
135	Retinal Changes in an ATP-Induced Model of Retinal Degeneration. *Frontiers in Neuroanatomy*, **2016**, 10, 46	3.6	13
134	Home Monitoring of Retinal Sensitivity on a Tablet Device in Intermediate Age-Related Macular Degeneration. *Translational Vision Science and Technology*, **2018**, 7, 32	3.3	13
133	Intravitreal therapy in bilateral neovascular age-related macular degeneration. *Ophthalmology*, **2014**, 121, 2073-4	7.3	12

132	Assessing residual visual function in severe vision loss **2014**, 55, 1332-8		12
131	Retinal venular caliber predicts visual outcome after intravitreal ranibizumab injection treatments for neovascular AMD **2012**, 53, 37-41		12
130	Nitration of tyrosines in complement factor H domains alters its immunological activity and mediates a pathogenic role in age related macular degeneration. *Oncotarget*, **2017**, 8, 49016-49032	3.3	12
129	Living with Geographic Atrophy: An Ethnographic Study. *Ophthalmology and Therapy*, **2019**, 8, 115-124	5	12
128	Age-related macular degeneration (AMD): More than meets the eye. The role of multimodal imaging in today's management of AMD-A review. *Clinical and Experimental Ophthalmology*, **2020**, 48, 983-995	2.4	12
127	Charles Bonnet Syndrome in Advanced Retinitis Pigmentosa. *Ophthalmology*, **2015**, 122, 1951-3	7.3	11
126	Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2015**, 253, 1347-54	3.8	11
125	Interpretation of Subretinal Fluid Using OCT in Intermediate Age-Related Macular Degeneration. *Ophthalmology Retina*, **2018**, 2, 792-802	3.8	11
124	Outcomes and Predictive Factors After Cataract Surgery in Patients With Neovascular Age-related Macular Degeneration. The Fight Retinal Blindness! Project. *American Journal of Ophthalmology*, **2018**, 190, 50-57	4.9	11
123	Effect of simvastatin on retinal vascular caliber: the Age-Related Maculopathy Statin Study. *Acta Ophthalmologica*, **2013**, 91, e418-9	3.7	11
122	Retinal vascular caliber and macular telangiectasia type 2. *Ophthalmology*, **2009**, 116, 319-23	7.3	11
121	Generating mouse models of retinal disease using ENU mutagenesis. *Vision Research*, **2002**, 42, 479-85	2.1	11
120	Do Beta 2-Glycoprotein I Disulfide Bonds Protect the Human Retina in the Setting of Age-Related Macular Degeneration?. *Antioxidants and Redox Signaling*, **2016**, 24, 32-8	8.4	10
119	Gene-environment interactions and aging visual function: a classical twin study. *Ophthalmology*, **2009**, 116, 263-9	7.3	10
118	Adaptation mechanisms, eccentricity profiles, and clinical implementation of red-on-white perimetry. *Optometry and Vision Science*, **2008**, 85, 309-17	2.1	10
117	Age-related macular degeneration and mortality: the Melbourne Collaborative Cohort Study. *Eye*, **2017**, 31, 1345-1357	4.4	10
116	ANALYSIS OF FLUID VOLUME AND ITS IMPACT ON VISUAL ACUITY IN THE FLUID STUDY AS QUANTIFIED WITH DEEP LEARNING. *Retina*, **2021**, 41, 1318-1328	3.6	10
115	Artificial Intelligence Algorithms for Analysis of Geographic Atrophy: A Review and Evaluation. *Translational Vision Science and Technology*, **2020**, 9, 57	3.3	10

114	Predicting Progression of Age-Related Macular Degeneration Using OCT and Fundus Photography. *Ophthalmology Retina*, **2021**, 5, 118-125	3.8	10
113	A Tablet-Based Retinal Function Test in Neovascular Age-Related Macular Degeneration Eyes and At-Risk Fellow Eye. *Translational Vision Science and Technology*, **2018**, 7, 2	3.3	10
112	Survival Bias When Assessing Risk Factors for Age-Related Macular Degeneration: A Tutorial with Application to the Exposure of Smoking. *Ophthalmic Epidemiology*, **2017**, 24, 229-238	1.9	9
111	Longitudinal Assessment of Rod Function in Intermediate Age-Related Macular Degeneration With and Without Reticular Pseudodrusen **2019**, 60, 1511-1518		9
110	Heritability of the spatial distribution and peak density of macular pigment: a classical twin study. *Eye*, **2012**, 26, 1217-25	4.4	9
109	Novel measures of cardiovascular health and its association with prevalence and progression of age-related macular degeneration: the CHARM Study. *BMC Ophthalmology*, **2008**, 8, 25	2.3	9
108	AMD: to supplement or not?. *Clinical and Experimental Ophthalmology*, **2004**, 32, 341-3	2.4	9
107	Dual roles of different redox forms of complement factor H in protecting against age related macular degeneration. *Free Radical Biology and Medicine*, **2018**, 129, 237-246	7.8	9
106	Repeatability of Retinal Sensitivity Measurements Using a Medmont Dark-Adapted Chromatic Perimeter in Healthy and Age-Related Macular Degeneration Cases. *Translational Vision Science and Technology*, **2018**, 7, 3	3.3	9
105	Topographic Rod Recovery Profiles after a Prolonged Dark Adaptation in Subjects with Reticular Pseudodrusen. *Ophthalmology Retina*, **2018**, 2, 1206-1217	3.8	8
104	Nanosecond Laser Treatment for Age-Related Macular Degeneration Does Not Induce Focal Vision Loss or New Vessel Growth in the Retina **2018**, 59, 731-745		8
103	Properties of the Impact of Vision Impairment and Night Vision Questionnaires Among People With Intermediate Age-Related Macular Degeneration. *Translational Vision Science and Technology*, **2019**, 8, 3	3.3	8
102	Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2012**, 40, 59-66	2.4	8
101	New Treatment Modalities for Geographic Atrophy. *Asia-Pacific Journal of Ophthalmology*, **2017**, 6, 508-513	3.5	8
100	Age Related Macular Degeneration and Total Hip Replacement Due to Osteoarthritis or Fracture: Melbourne Collaborative Cohort Study. *PLoS ONE*, **2015**, 10, e0137322	3.7	8
99	Optical coherence tomography-guided retinal prosthesis design: model of degenerated retinal curvature and thickness for patient-specific devices. *Artificial Organs*, **2014**, 38, E82-94	2.6	8
98	Testing protocol and recruitment in the genes in myopia twin study. *Ophthalmic Epidemiology*, **2008** , 15, 140-7	1.9	8
97	Non-mydriatic digital macular photography: how good is the second eye photograph?. *Ophthalmic Epidemiology*, **2009**, 16, 254-61	1.9	8

96	Imaging Lenticular Autofluorescence in Older Subjects **2017**, 58, 4940-4947		7
95	Gaming to improve vision: 21st century self-monitoring for patients with age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2018**, 46, 480-484	2.4	7
94	Performance of a Defect-Mapping Microperimetry Approach for Characterizing Progressive Changes in Deep Scotomas. *Translational Vision Science and Technology*, **2019**, 8, 16	3.3	7
93	Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2017**, 45, 143-151	2.4	7
92	Is renal function associated with early age-related macular degeneration?. *Optometry and Vision Science*, **2014**, 91, 860-4	2.1	7
91	Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period. *Eye*, **2012**, 26, 958-66	4.4	7
90	A review of drug options in age-related macular degeneration therapy and potential new agents. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 2355-68	4	7
89	Choroidal lesions preceding symptom onset in birdshot chorioretinopathy. *JAMA Ophthalmology*, **2006**, 124, 1057-8		7
88	Reticular pseudodrusen: A critical phenotype in age-related macular degeneration. *Progress in Retinal and Eye Research*, **2021**, 101017	20.5	7
87	Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease. *Scientific Reports*, **2020**, 10, 12165	4.9	7
86	Examining the added value of microperimetry and low luminance deficit for predicting progression in age-related macular degeneration. *British Journal of Ophthalmology*, **2021**, 105, 711-715	5.5	7
85	Age-related macular degeneration in ethnically diverse Australia: Melbourne Collaborative Cohort Study. *Ophthalmic Epidemiology*, **2015**, 22, 75-84	1.9	6
84	Relationship between reticular pseudodrusen and choroidal thickness in intermediate age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2018**, 46, 485-494	2.4	6
83	Age-related macular degeneration phenotypes associated with mutually exclusive homozygous risk variants in CFH and HTRA1 genes. *Retina*, **2015**, 35, 989-98	3.6	6
82	Analysis of glutathione S-transferase Pi isoform (GSTP1) single-nucleotide polymorphisms and macular telangiectasia type 2. *International Ophthalmology*, **2010**, 30, 645-50	2.2	6
81	Intravitreous injections. *Clinical and Experimental Ophthalmology*, **2006**, 34, 388-90	2.4	6
80	Association Study of Mannose-Binding Lectin Levels and Genetic Variants in Lectin Pathway Proteins with Susceptibility to Age-Related Macular Degeneration: A Case-Control Study. *PLoS ONE*, **2015**, 10, e0134107	3.7	6
79	Association of the del443ins54 at the ARMS2 locus in Indian and Australian cohorts with age-related macular degeneration. *Molecular Vision*, **2013**, 19, 822-8	2.3	6

78	Mirror-image congenital esotropia in monozygotic twins. *Journal of Pediatric Ophthalmology and Strabismus*, **2006**, 43, 170-1	0.9	6
77	OCT Signs of Early Atrophy in Age-Related Macular Degeneration: Interreader Agreement: Classification of Atrophy Meetings Report 6. *Ophthalmology Retina*, **2021**,	3.8	6
76	IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN. *Retina*, **2021**, 41, 2221-2228	3.6	6
75	Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study. *Contemporary Clinical Trials Communications*, **2017**, 6, 105-114	1.8	5
74	Prophylactic laser in age-related macular degeneration: the past, the present and the future. *Eye*, **2018**, 32, 972-980	4.4	5
73	Does aspirin increase the risk of age-related macular degeneration?. *Expert Opinion on Drug Safety*, **2014**, 13, 691-3	4.1	5
72	Human pluripotent stem cell strategies for age-related macular degeneration. *Optometry and Vision Science*, **2014**, 91, 887-93	2.1	5
71	Almost total protection from age-related macular degeneration by haplotypes of the Regulators of Complement Activation. *Genomics*, **2011**, 98, 412-21	4.3	5
70	Role of genetic factors in lower- and higher-order aberrations--the genes in myopia twin study. *Ophthalmic Research*, **2009**, 41, 142-7	2.9	5
69	The genetics of age-related macular degeneration. *Australasian journal of optometry, The*, **2001**, 84, 182-189	1.7	5
68	Rasch Analysis of the Independent Mobility Questionnaire. *Optometry and Vision Science*, **2016**, 93, 181-7	2.1	5
67	Presymptomatic Retinal Sensitivity Changes in Intermediate Age-Related Macular Degeneration Associated With New Retinal Fluid. *Translational Vision Science and Technology*, **2019**, 8, 3	3.3	5
66	Uptake, Persistence, and Performance of Weekly Home Monitoring of Visual Field in a Large Cohort of Patients With Glaucoma. *American Journal of Ophthalmology*, **2021**, 223, 286-295	4.9	5
65	Psychosocial assessment of potential retinal prosthesis trial participants. *Australasian journal of optometry, The*, **2019**, 102, 506-512	2.7	4
64	Relationship Between Rod-Mediated Sensitivity, Low-Luminance Visual Acuity, and Night Vision Questionnaire in Age-Related Macular Degeneration. *Translational Vision Science and Technology*, **2020**, 9, 30	3.3	4
63	Seven-year Trends in Visual Acuity at First Presentation in Patients with Neovascular AMD. *Ophthalmology*, **2017**, 124, 270-272	7.3	4
62	Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated?. *Medical Journal of Australia*, **2013**, 198, 260-1	4	4
61	Clinical audit as an educative tool for optometrists: an intervention study in age-related macular degeneration. *Ophthalmic and Physiological Optics*, **2021**, 41, 53-72	4.1	4

60	New Technologies to Study Functional Genomics of Age-Related Macular Degeneration. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 604220	5.7	4
59	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular age-related macular degeneration: a prospective study from a long-term observational data set. The Fight Retinal Blindness! Project. *Clinical and Experimental Ophthalmology*, **2018**, 46, 266-274	2.4	3
58	Image processing for visual prostheses: A clinical perspective **2013**,		3
57	Hydroxychloroquine retinopathy: screening needed to prevent blindness. *Medical Journal of Australia*, **2010**, 192, 668-9	4	3
56	Marked discordance for myopia in female monozygotic twins. *Clinical and Experimental Ophthalmology*, **2006**, 34, 285-7	2.4	3
55	Grand Challenges in global eye health: a global prioritisation process using Delphi method.. *The Lancet Healthy Longevity*, **2022**, 3, e31-e41	9.5	3
54	Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. *JAMA Ophthalmology*, **2020**, 138, 1234-1240	3.9	3
53	Validation of an Automated Quantification of Relative Ellipsoid Zone Reflectivity on Spectral Domain-Optical Coherence Tomography Images. *Translational Vision Science and Technology*, **2020**, 9, 17	3.3	3
52	NATURAL HISTORY OF QUANTITATIVE AUTOFLUORESCENCE IN INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. *Retina*, **2021**, 41, 694-700	3.6	3
51	Deficits in Monocyte Function in Age Related Macular Degeneration: A Novel Systemic Change Associated With the Disease. *Frontiers in Medicine*, **2021**, 8, 634177	4.9	3
50	Polymorphisms in the APOE gene and the location of retinal fluid in eyes with neovascular age-related macular degeneration. *Retina*, **2014**, 34, 2367-75	3.6	2
49	Younger siblings, C-reactive protein, and risk of age-related macular degeneration. *American Journal of Epidemiology*, **2013**, 177, 933-43	3.8	2
48	The dot-and-fleck retinopathy of X linked Alport syndrome is independent of complement factor H (CFH) gene polymorphisms. *British Journal of Ophthalmology*, **2009**, 93, 379-82	5.5	2
47	Sorsby's Fundus Dystrophy: a case report to raise awareness of the disease and potential future treatments. *Clinical and Experimental Ophthalmology*, **2009**, 37, 325-7	2.4	2
46	Wound leak after intravitreal injection of bevacizumab. *Retinal Cases and Brief Reports*, **2008**, 2, 245-6	1.1	2
45	Analysis of the RDS/peripherin gene in age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2007**, 35, 194-5	2.4	2
44	Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration: A Mendelian Randomization Study. *JAMA Ophthalmology*, **2021**,	3.9	2
43	TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. *Ophthalmology Science*, **2021**, 100076		2

42	Treatment of age-related macular degeneration. *Australian Prescriber*, **2012**, 35, 90-93	1.4	2
41	Association between Patient-Reported Outcomes and Time to Late Age-Related Macular Degeneration in the Laser Intervention in Early Stages of Age-Related Macular Degeneration Study. *Ophthalmology Retina*, **2020**, 4, 881-888	3.8	2
40	Subthreshold Nanosecond Laser in Age-Related Macular Degeneration: Observational Extension Study of the LEAD Clinical Trial. *Ophthalmology Retina*, **2021**, 5, 1196-1203	3.8	2
39	USING MICROPERIMETRY AND LOW-LUMINANCE VISUAL ACUITY TO DETECT THE ONSET OF LATE AGE-RELATED MACULAR DEGENERATION: A LEAD Study Report. *Retina*, **2021**, 41, 1094-1101	3.6	2
38	Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration. *American Journal of Ophthalmology*, **2021**, 233, 8-17	4.9	2
37	Can the Onset of Atrophic Age-Related Macular Degeneration Be an Acceptable Endpoint for Preventative Trials?. *Ophthalmologica*, **2020**, 243, 399-403	3.7	1
36	Implications of Analysis Unit on Epidemiology of Multimodal Imaging-Defined Reticular Pseudodrusen: When 2 Eyes Are Better Than 1. *JAMA Ophthalmology*, **2020**, 138, 477-478	3.9	1
35	Lifestyle and age-related macular degeneration. *Expert Review of Ophthalmology*, **2009**, 4, 79-102	1.5	1
34	Concordant bilateral Duane's Retraction Syndrome (type 1) in female monozygotic twins. *Clinical and Experimental Ophthalmology*, **2006**, 34, 495-7	2.4	1
33	Treatment and Prevention of Age-Related Macular Degeneration. *Journal of Pharmacy Practice and Research*, **2004**, 34, 53-57	0.7	1
32	Hyporeflective Cores within Drusen: Association with Progression of Age-Related Macular Degeneration and Impact on Visual Sensitivity. *Ophthalmology Retina*, **2021**,	3.8	1
31	Comparison of Visual Function Tests in Intermediate Age-Related Macular Degeneration. *Translational Vision Science and Technology*, **2021**, 10, 14	3.3	1
30	Baseline characteristics and age-related macular degeneration in participants of the "ASPirin in Reducing Events in the Elderly" (ASPREE)-AMD trial. *Contemporary Clinical Trials Communications*, **2020**, 20, 100667	1.8	1
29	Treating Neovascular Age-Related Macular Degeneration-So Much More to Learn. *JAMA Ophthalmology*, **2020**, 138, 1051-1052	3.9	1
28	Focus on Survival Analysis for Eye Research **2021**, 62, 7		1
27	Model Structure Uncertainty in the Characterization and Growth of Geographic Atrophy. *Translational Vision Science and Technology*, **2021**, 10, 2	3.3	1
26	Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater. *Clinical and Experimental Ophthalmology*, **2021**, 49, 570-578	2.4	1
25	Binding of Gtf2i-/II transcription factors to the ARMS2 gene leads to increased circulating HTRA1 in AMD patients and in vitro. *Journal of Biological Chemistry*, **2021**, 296, 100456	5.4	1

24	Investigating the discrepancy between MAIA and MP-1 microperimetry results. *Ophthalmic and Physiological Optics*, **2021**, 41, 1231-1240	4.1	1
23	A clinical perspective on the expanding role of artificial intelligence in age-related macular degeneration.. *Australasian journal of optometry, The*, **2022**, 1-6	2.7	0
22	Multi-focal electro-retinogram response following sub-threshold nano-second laser intervention in age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2020**, 48, 938-945	2.4	0
21	Dose Response in the Subthreshold Nanosecond Laser Trial in Early Stages of AMD: A LEAD Study Report. *Ophthalmic Surgery Lasers and Imaging Retina*, **2021**, 52, 380-386	1.4	0
20	Deep Learning Applied to Automated Segmentation of Geographic Atrophy in Fundus Autofluorescence Images. *Translational Vision Science and Technology*, **2021**, 10, 2	3.3	0
19	A comparison of methods to estimate the survivor average causal effect in the presence of missing data: a simulation study. *BMC Medical Research Methodology*, **2019**, 19, 223	4.7	0
18	PERIPHERAL RETINAL DRUSEN-LIKE DEPOSITS IN GUCY2C CONGENITAL SECRETORY DIARRHEA SYNDROME. *Retinal Cases and Brief Reports*, **2021**, 15, 89-92	1.1	0
17	Is There a Case for Case-Control Studies in the Exploration of Retrospective Data Sets?. *JAMA Ophthalmology*, **2021**, 139, 309-310	3.9	0
16	Author reply: To PMID 23021093. *Ophthalmology*, **2013**, 120, e69	7.3	
15	Pluripotent stem cell-based models to investigate retinal pigmented epithelium function and disease. *Drug Discovery Today: Disease Models*, **2013**, 10, e231-e236	1.3	
14	Author reply: To PMID 25109931. *Ophthalmology*, **2015**, 122, e53-4	7.3	
13	Bionic Eyes: Vision Restoration Through Electronic or Photovoltaic Stimulation. *Pancreatic Islet Biology*, **2014**, 257-273	0.4	
12	FIVE OF THE AUTHORS REPLY. *American Journal of Epidemiology*, **2009**, 170, 532-533	3.8	
11	2006 Council Lecture: Lancelot to the rescue: realizing the promise of genomic medicine. *Clinical and Experimental Ophthalmology*, **2007**, 35, 403-8	2.4	
10	Australian Angiogram Review Panel--monitoring the use of photodynamic therapy with verteporfin. *Clinical and Experimental Ophthalmology*, **2006**, 34, 550-6	2.4	
9	New treatments for age-related macular degeneration. *Lancet, The*, **2007**, 370, 1481	40	
8	Genes and Age-Related Macular Degeneration **2005**, 63-78		
7	Response to Balancing the risks and benefits in AMD *Clinical and Experimental Ophthalmology*, **2005**, 33, 110-111	2.4	

6	Age Changes in Bruch's Membrane and Related Structures **2006**, 1029-1039	
5	Reply. *American Journal of Ophthalmology*, **2018**, 185, 123-124	4.9
4	Assessment and monitoring of retinal function in age-related macular degeneration **2014**, 114-123	
3	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. *Essentials in Ophthalmology*, **2016**, 31-65	0.2
2	Reply. *Ophthalmology*, **2019**, 126, e92-e93	7.3
1	Relationship between reticular pseudodrusen and choroidal thickness in intermediate age-related macular degeneration: response. *Clinical and Experimental Ophthalmology*, **2018**, 46, 967-968	2.4